Ideas to Action:

Independent research for global prosperity

CGD Policy Blogs


Progress and Priorities in Promoting Transparency along the COVID-19 Vaccine Value Chain

CGD co-hosted an online event in November with the U4 Anti-Corruption Resource Centre to discuss the progress and challenges in pursuit of a transparent and equitable roll out of COVID-19 vaccine. Following on earlier calls for transparency, this event built on new research from U4 and pointed to two main areas of progress as well as two priorities going forward.

An image of a doctor working on a laptop.

The Opportunity Cost Neglect in Healthcare: Bad Choices Are Not About Overspend But Life Lost

In the language of economists, opportunity cost refers to the return or other forms of benefit that we could have received, but gave up, to take another course of action. In mathematical terms, it is the difference between the utility of what we have chosen and that from the foregone choice. Or, in much simpler terms, its what’s given up when making a choice. A positive opportunity cost shows that we made a good decision.

As Antimicrobial Resistance Advances, We Need Action to Stop a Predictable Catastrophe

Antibiotic resistance (AMR) is not a new problem. However, the global community has been slow to implement recommended policy measures and achieve systemic change. CGD will launch a working group on antimicrobial resistance—seeking to improve antibiotic access and R&D in low- and middle-income countries, and reduce unnecessary use.

We Should Prepare for an Omicron COVID-19 Wave by Prioritising Cost-Effective Essential Emergency Critical Care Now

The new Omicron variant of COVID-19  may be more transmissible and more capable of evading vaccines than older variants due to its high number of mutations. There is a real concern that it could spread rapidly throughout the world and lead to another wave  of critically ill patients in low-and middle income countries (LMICs), where vaccine coverage remains low.

The Benefits and Challenges of Developing and Revising Health Benefits Packages: Insights From Technical Experts in Eleven Low- and Middle-Income Countries

We worked with the Joint Learning Network (JLN) Efficiency Collaborative to gain insights from Collaborative members who represent technical staff and decision-makers working at the heart of health benefit packages development and revisions in eleven low-and middle-income countries in Africa and Asia. This blog summarizes the initial results from a survey conducted earlier this year to capture their views and experiences on the HPB development and updating process.

We Should Track Global Vaccine Manufacturing Better - Here Is Why, and How

Poor understanding about vaccine capacity was one of the reasons why the world did not have the infrastructure needed to manufacture sufficient doses. This blogs proposes three actions to start tracking manufacturing capacity better and create robust estimates for the world’s vaccine manufacturing capacity.

Before Recommending the RTS,S Malaria Vaccine for Wider Use, WHO Should Address Three Key Considerations

Last month, the world woke up to promising news on malaria prevention: administering an existing malaria vaccine (RTS,S) in addition to antimalarial drugs before the rainy season reduced child hospitalizations and deaths by approximately 70 percent in Burkina Faso and Mali. These results arrived ahead of a forthcoming decision from the World Health Organization on whether to recommend RTS,S for broader use. This blog argues that WHO should consider value for money and address three key considerations before making their reccomendation.

C19 Economics site

Three Key Gaps in the Health Economics Research on COVID-19, and Why It Matters

The online platform C19economics was created to support researchers and decision makers by collating the health economic literature published on the COVID-19 pandemic into an easily searchable repository. After reviewing the literature, we found three notable gaps in coverage in terms of geographical focus and topic areas.